RT Journal Article
SR Electronic
T1 GLP-1 enhances beta-cell response to protein ingestion independent of glycemia and bariatric surgery amplifies it
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.22.23297377
DO 10.1101/2023.10.22.23297377
A1 Rayas, Maria
A1 Gastaldelli, Amalia
A1 Honka, Henri
A1 Pezzica, Samantha
A1 Carli, Fabrizia
A1 Peterson, Richard
A1 DeFronzo, Ralph
A1 Salehi, Marzieh
YR 2024
UL http://medrxiv.org/content/early/2024/01/11/2023.10.22.23297377.abstract
AB Background The glycemic-independent actions of glucagon-like peptide 1 (GLP-1) in the prandial state in humans are largely unknown. Protein ingestion stimulates beta-cell secretion without changing plasma glucose concentration. We examined the contribution of endogenous GLP-1 to glucose metabolism and beta-cell response to protein ingestion under basal glucose concentrations, and whether these responses are affected by rerouted gut after gastric bypass (GB) or sleeve gastrectomy (SG).Methods Insulin secretion rate (ISR) and glucose fluxes during a 50-gram oral protein load were compared between 10 non-diabetic individuals with GB, 9 matched subjects with SG and 7 non-operated controls (CN) with and without intravenous infusion of exendin-(9–39) [Ex-9], a specific GLP-1 receptor (GLP-1R) antagonist.Results Blocking GLP-1R increased plasma glucose concentration before and after protein ingestion and decreased beta-cell sensitivity to glucose in the first 30 minutes of protein ingestion (p<0.05) in all 3 groups. However, reduction in the premeal ISR by Ex-9 infusion only was observed in CN (p<0.05 for interaction), whereas diminished prandial ISR3h by GLP-1R blockade was observed in GB and SG and not in controls (p<0.05 for interaction). Also, GLP-1R blockade enhanced post-protein insulin action in GB and SG, but not in CN. Endogenous glucose production (EGP) during the first hour after protein ingestion was increased in all 3 groups but EGP3h was accentuated by Ex-9 infusion only in GB (p<0.05 for interaction).Conclusion These findings are consistent with both a glucose-independent pancreatic and extra-pancreatic role for GLP-1 during protein ingestion in humans that are exaggerated by bariatric surgery.Trial registration This study was registered at Clinical Trials.Gov: NCT02823665Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02823665Funding StatementThis study was funded by grants from the National Institute of Health, DK105379 (MS), KL2 TR002646 (MR), and in part by National Center for Advancing Translational Sciences, National Institute of Health grant UL1 TR002645. A.G. acknowledges the financial support from the European Unions Horizon 2020 Research and Innovation Programme for the project Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA). SOPHIA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking received support from the European Unions Horizon 2020 research and innovation program, EFPIA, T1D Exchange, JDRF, and Obesity Action Coalition. The communication reflects the authors view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Texas Health San Antonio gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.